BR112022001575A2 - Formulações de anticorpos anti-pvrig e usos dos mesmos - Google Patents

Formulações de anticorpos anti-pvrig e usos dos mesmos

Info

Publication number
BR112022001575A2
BR112022001575A2 BR112022001575A BR112022001575A BR112022001575A2 BR 112022001575 A2 BR112022001575 A2 BR 112022001575A2 BR 112022001575 A BR112022001575 A BR 112022001575A BR 112022001575 A BR112022001575 A BR 112022001575A BR 112022001575 A2 BR112022001575 A2 BR 112022001575A2
Authority
BR
Brazil
Prior art keywords
antibody formulations
pvrig antibody
pvrig
formulations
liquid pharmaceutical
Prior art date
Application number
BR112022001575A
Other languages
English (en)
Inventor
Henry Adewoye Adeboye
Cohen Dayag Anat
John Hunter
Jun Lu
Mark White
Michael Buckley
Original Assignee
Compugen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Compugen Ltd filed Critical Compugen Ltd
Publication of BR112022001575A2 publication Critical patent/BR112022001575A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

formulações de anticorpos anti-pvrig e usos dos mesmos. trata se de anticorpos anti pvrig e formulações farmacêuticas líquidas estáveis dos mesmos.
BR112022001575A 2019-07-29 2020-07-28 Formulações de anticorpos anti-pvrig e usos dos mesmos BR112022001575A2 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962880021P 2019-07-29 2019-07-29
US201962893051P 2019-08-28 2019-08-28
US201962930206P 2019-11-04 2019-11-04
US202062968660P 2020-01-31 2020-01-31
US202062985702P 2020-03-05 2020-03-05
US202063009367P 2020-04-13 2020-04-13
PCT/US2020/043921 WO2021021837A2 (en) 2019-07-29 2020-07-28 Anti-pvrig antibodies formulations and uses thereof

Publications (1)

Publication Number Publication Date
BR112022001575A2 true BR112022001575A2 (pt) 2022-04-19

Family

ID=72243187

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022001575A BR112022001575A2 (pt) 2019-07-29 2020-07-28 Formulações de anticorpos anti-pvrig e usos dos mesmos

Country Status (11)

Country Link
US (1) US20220280643A1 (pt)
EP (1) EP4003417A2 (pt)
JP (1) JP2022542505A (pt)
KR (1) KR20220041881A (pt)
CN (1) CN114615993A (pt)
AU (1) AU2020323926A1 (pt)
BR (1) BR112022001575A2 (pt)
CA (1) CA3149093A1 (pt)
IL (1) IL290141A (pt)
MX (1) MX2022001146A (pt)
WO (1) WO2021021837A2 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202216778A (zh) 2020-07-15 2022-05-01 美商安進公司 Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷
EP4222172A1 (en) * 2020-09-30 2023-08-09 Compugen Ltd. Combination therapy with anti-pvrig antibodies formulations, anti-tigit antibodies, and anti-pd-1 antibodies
CA3207791A1 (en) * 2021-02-09 2022-08-18 Shanghai Junshi Biosciences Co., Ltd. Anti-cd112r antibody and use thereof
CA3231320A1 (en) 2021-09-15 2023-03-23 Zhiliang CAO Protein specifically binding to pd-1 and pharmaceutical use thereof
WO2024027824A1 (zh) * 2022-08-05 2024-02-08 上海君实生物医药科技股份有限公司 抗cd112r抗体药物组合物及其用途
WO2024032700A1 (en) * 2022-08-10 2024-02-15 Beigene, Ltd. Anti-pvrig antibodies and methods of use
WO2024046245A1 (zh) * 2022-08-31 2024-03-07 石药集团巨石生物制药有限公司 抗pvrig抗体及其应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9714A (en) 1853-05-10 Machine fob making hook-headed spikes
US289A (en) 1837-07-19 Cooking-stove
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
CA2006596C (en) 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
EP0640094A1 (en) 1992-04-24 1995-03-01 The Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ATE458007T1 (de) 1998-04-20 2010-03-15 Glycart Biotechnology Ag Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
ES2694002T3 (es) 1999-01-15 2018-12-17 Genentech, Inc. Polipéptido que comprende una región Fc de IgG1 humana variante
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Hakko Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
BR0309145A (pt) 2002-04-09 2005-02-01 Kyowa Hakko Kogyo Kk Células das quais o genoma é modificado
EP1610820B2 (en) * 2003-04-04 2013-08-21 Genentech, Inc. High concentration antibody and protein formulations
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
DK3259597T3 (da) * 2015-02-19 2022-05-09 Compugen Ltd Pvrig-polypeptider og fremgangsmåder til behandling
PT3295951T (pt) 2015-02-19 2020-07-21 Compugen Ltd Anticorpos anti-pvrig e métodos de utilização
SI3347379T1 (sl) * 2016-08-17 2020-04-30 Compugen Ltd. ANTI-TIGIT protitelesa, ANTI-PVRIG protitelesa in njihove kombinacije
AU2017380842A1 (en) * 2016-12-23 2019-07-11 Serum Institute Of India Private Limited Improved methods for enhancing antibody productivity in mammalian cell culture and minimizing aggregation during downstream, formulation processes and stable antibody formulations obtained thereof

Also Published As

Publication number Publication date
KR20220041881A (ko) 2022-04-01
IL290141A (en) 2022-03-01
CA3149093A1 (en) 2021-02-04
WO2021021837A2 (en) 2021-02-04
WO2021021837A3 (en) 2021-03-11
US20220280643A1 (en) 2022-09-08
EP4003417A2 (en) 2022-06-01
CN114615993A (zh) 2022-06-10
MX2022001146A (es) 2022-03-17
AU2020323926A1 (en) 2022-03-10
JP2022542505A (ja) 2022-10-04

Similar Documents

Publication Publication Date Title
BR112022001575A2 (pt) Formulações de anticorpos anti-pvrig e usos dos mesmos
CY1123783T1 (el) Antiσωμαta enanti-b7-h3 και συζευγματα αντισωματος φαρμακου
BR112018075649A2 (pt) anticorpos anti-b7-h3 e conjugados de fármaco de anticorpo
BR112018075653A2 (pt) anticorpos anti-b7-h3 e conjugados anticorpo fármaco
BR112020002012A8 (pt) Anticorpos anti-cd39, composições que compreendem anticorpos anti-cd39 e métodos de utilização de anticorpos anti-cd39
CL2019001740A1 (es) Novedoso conjugado de amanitina.
CR20170600A (es) Anticuerpos del factor x1 y métodos de uso
MA50949B1 (fr) Anticorps anti-ctla-4 et leurs procédés d'utilisation
MA44594B1 (fr) Anticorps anti-ctla-4 et méthodes d'utilisation de ceux-ci
CL2020002042A1 (es) Dominios variables de anticuerpos que se dirigen al receptor nkg2d.
BR112017006178A2 (pt) região fc, anticorpos, formulação farmacêutica e usos dos anticorpos
BR112016026811A2 (pt) formulação de anticorpo
MA50134A (fr) Anticorps anti-protéine 1 contenant un domaine anti-cub (cdcp1), conjugués anticorps-médicament et leurs méthodes d'utilisation
EA201900562A1 (ru) Бис-октагидрофенантрена карбоксамиды и их белковые конъюгаты
BR112018075630A2 (pt) anticorpos anti-cd98 e conjugados de fármaco de anticorpo
MA51903A (fr) Formulations d'anticorps b7-h4
CL2008002092A1 (es) Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas.
EA202092202A1 (ru) Конструкции антител к ror
BR112021016056A2 (pt) Anticorpos de claudina 6 e usos dos mesmos
CO2021010697A2 (es) Formulación de anticuerpos terapéuticos
BR112022008558A2 (pt) Método de tratamento para câncer, tratamento de combinação de nivolumabe e anticorpos anti-pvrig, e, uso
JOP20210014A1 (ar) تركيبات مضادات fcrn وطرق استخدامها
MA51902A (fr) Schémas posologiques d'anticorps b7-h4
BR112018072125A2 (pt) "composições farmacêuticas e regimes de dosagem para uso clínico de anticorpos de antiantígeno sanguíneo de célula dendrítica 2
EA201792312A1 (ru) Конструкции на основе калихеамицина и способы их применения